ECEvelyne Castel-Lacanal

Evelyne Castel-Lacanal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Evelyne Castel-Lacanal has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Response to the Letter to the Editor Regarding “One‐Year Transcutaneous Tibial Nerve Stimulation Treatment Persistence in Lower Urinary Tract Dysfunction: Clinical and Urodynamic Associated Factors in a Prospective Observational Study”

    by Damien Prat, Evelyne Castel‐Lacanal, Thibaut Brierre, Gaetane Foures, Camille Cormier, Xavier De Boissezon, David Gasq, Philippe Marque, Xavier Gamé, Emmeline Montané

  • Open Access

    One‐Year Transcutaneous Tibial Nerve Stimulation Treatment Persistence in Lower Urinary Tract Dysfunction: Clinical and Urodynamic Associated Factors in a Prospective Observational Study

    by Damien Prat, Evelyne Castel‐Lacanal, Thibaut Brierre, Gaetane Foures, Camille Cormier, Xavier De Boissezon, David Gasq, Philippe Marque, Xavier Gamé, Emmeline Montané

    Aims: To assess 1‐year Transcutaneous Tibial Nerve Stimulation (TTNS) treatment persistence in routine clinical care and to explore clinical and urodynamic factors associated with treatment persistence in patients with lower urinary tract dysfunction (LUTD). Methods: A prospective, monocentric, observational cohort study was conducted between October 2022 and January 2024 (RnIPH 2022‐109). Adult patients with LUTD for whom TTNS was prescribed and initiated at home (20 min/day) were consecutively included. Baseline assessment included clinical characteristics, urodynamic findings, and patient‐reported outcomes, including the Patient Global Impression of Severity (PGI‐S), Patient Global Impression of Improvement (PGI‐I), Urinary Symptom Profile (USP), and QUALIVEEN‐Short Form (QSF). Treatment persistence and patient‐reported outcomes were assessed at 2–4 months, and persistence was reassessed at 12 months. Persistence over time was described using a Kaplan–Meier analysis, and factors associated with time to discontinuation were explored using Cox proportional hazards models. Results: Fifty‐six patients initiated TTNS, including 32 (57%) with neurological LUTD. At 1 year, 21/56 patients (38%) remained persistent, including 21/34 (62%) among the device purchasers. Persistence was higher in neurological (56%, 18/32) than in non‐neurological patients (13%, 3/24), and neurological etiology was associated with a lower hazard of discontinuation in multivariable Cox analysis (adjusted HR: 0.42, 95% CI: 0.18–0.99, p = 0.047). Lower symptom burden and greater perceived improvement at 2–4 months were associated with both device acquisition and long‐term persistence, particularly through lower PGI‐S, PGI‐I, USP‐OAB, and QSF scores. Overactive urethral sphincter was more frequent in neurological patients ( p = 0.008) and among persistent purchasers ( p = 0.006). TTNS was well tolerated, with only one minor adverse event reported. Conclusion: TTNS treatment persistence in routine care appeared to depend on both clinical profile and early patient‐reported outcomes. The 2–4‐month reassessment emerged as a key decision point for evaluating long‐term TTNS treatment persistence. These findings support further investigation into the relationship between neuro‐urological phenotypes and long‐term TTNS treatment persistence.


  • Open Access

    Refining a Task Description Notation to Cover Perceptive, Cognitive, and Motor aspects of the HCI loop: Application to Post-stroke Rehabilitation Exercises

    by Axel Carayon, Célia Martinie, Philippe Palanque, Emmeline Montane, Evelyne Castel-Lacanal, Philippe Marque

  • Open Access

    A custom-made sling to achieve personal goals in shoulder pain or subluxation in the subacute stroke phase: a pilot study

    by Emmeline Montané, Magali Pradié, Inès Bigarre, Claire Lebely, Alizée Lelièvre, Camille Cormier, Jacqueline Butterworth, Benoît Lepage, Philippe Marque, Xavier de Boissezon, et al.

  • Open Access

    Effect of Early Treatment of Spasticity After Stroke on Motor Recovery: Protocol for the Baclotox Multicenter, Double-Blind, Double-Dummy Randomized Controlled Trial

    by Emmeline Montane, Nabila Brihmat, Camille Cormier, Claire Thalamas, Vanessa Rousseau, Gerard Tap, Xavier De Boissezon, Evelyne Castel-Lacanal, Baclotox Group, Philippe Marque

    Background: Individuals with poststroke hemiplegia often develop spasticity, which increases disability. Antispastic treatments such as baclofen and botulinum toxin are commonly prescribed in poststroke recovery. However, their impact on motor recovery, especially when administered within the first 2 months after stroke, remains unclear. Objective: This study aims to compare the motor recovery effects of botulinum toxin versus oral baclofen. The hypothesis is that botulinum toxin is more supportive of motor recovery than baclofen and enhances functional recovery. Methods: The study is a multicenter, controlled phase IV, comparative, prospective, randomized, double-blind, double-dummy, superiority trial to compare the toxin and baclofen, and a noninferiority trial to compare the toxin and the placebo. It focuses on the time course of the Fugl-Meyer Motor Assessment (FMA) as the primary outcome. The main inclusion criterion is patients with a single stroke in the past 2 months. Treatment comprises 1 intramuscular injection at treatment initiation and oral tablets for 4 months. Randomized patients are allocated to 3 arms: botulinum toxin with placebo baclofen, baclofen with placebo botulinum toxin, and placebo baclofen with placebo botulinum toxin. FMA scores are assessed at pretreatment, 1 month, and 3 months later. Spasticity, functional abilities, activities of daily living, pain, and quality of life are also evaluated. Adverse effects are monitored. A positive difference of 13 points in the FMA time course between the botulinum toxin and baclofen groups is considered a relevant effect. The data analysis plan involves linear regression models to compare primary and secondary outcomes, with adjustments for covariates such as age, center, and associated treatments. Subgroup analyses will examine proportional recovery profiles, and missing data in Fugl-Meyer scores will be addressed using imputation methods. Results: A total of 179 participants were randomized across 18 centers, with inclusions delayed due to the COVID-19 pandemic. As of December 2024, the data manager currently has all the data, and a review of data quality is in progress. No statistical analysis has been conducted so far, and the blind will be lifted after the analysis. Conclusions: This study identifies the most suitable spasticity treatment, considering the specificities of the stroke and constraints during the recovery phase. It will provide recommendations for the primary treatment of early spasticity post stroke. Trial Registration: ClinicalTrials.gov NCT02462317; https://clinicaltrials.gov/study/NCT02462317; European clinical trials (EudraCT) 2010-022881-28; https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022881-28/FR International Registered Report Identifier (IRRID): DERR1-10.2196/62951


  • Open Access

    Effect of Early Treatment of Spasticity After Stroke on Motor Recovery: Protocol for the Baclotox Multicenter, Double-Blind, Double-Dummy Randomized Controlled Trial (Preprint)

    by Emmeline Montane, Nabila Brihmat, Camille Cormier, Claire Thalamas, Vanessa Rousseau, Gerard Tap, Xavier De Boissezon, Evelyne Castel-Lacanal, Philippe Marque

    BACKGROUND Individuals with poststroke hemiplegia often develop spasticity, which increases disability. Antispastic treatments such as baclofen and botulinum toxin are commonly prescribed in poststroke recovery. However, their impact on motor recovery, especially when administered within the first 2 months after stroke, remains unclear. OBJECTIVE This study aims to compare the motor recovery effects of botulinum toxin versus oral baclofen. The hypothesis is that botulinum toxin is more supportive of motor recovery than baclofen and enhances functional recovery. METHODS The study is a multicenter, controlled phase IV, comparative, prospective, randomized, double-blind, double-dummy, superiority trial to compare the toxin and baclofen, and a noninferiority trial to compare the toxin and the placebo. It focuses on the time course of the Fugl-Meyer Motor Assessment (FMA) as the primary outcome. The main inclusion criterion is patients with a single stroke in the past 2 months. Treatment comprises 1 intramuscular injection at treatment initiation and oral tablets for 4 months. Randomized patients are allocated to 3 arms: botulinum toxin with placebo baclofen, baclofen with placebo botulinum toxin, and placebo baclofen with placebo botulinum toxin. FMA scores are assessed at pretreatment, 1 month, and 3 months later. Spasticity, functional abilities, activities of daily living, pain, and quality of life are also evaluated. Adverse effects are monitored. A positive difference of 13 points in the FMA time course between the botulinum toxin and baclofen groups is considered a relevant effect. The data analysis plan involves linear regression models to compare primary and secondary outcomes, with adjustments for covariates such as age, center, and associated treatments. Subgroup analyses will examine proportional recovery profiles, and missing data in Fugl-Meyer scores will be addressed using imputation methods. RESULTS A total of 179 participants were randomized across 18 centers, with inclusions delayed due to the COVID-19 pandemic. As of December 2024, the data manager currently has all the data, and a review of data quality is in progress. No statistical analysis has been conducted so far, and the blind will be lifted after the analysis. CONCLUSIONS This study identifies the most suitable spasticity treatment, considering the specificities of the stroke and constraints during the recovery phase. It will provide recommendations for the primary treatment of early spasticity post stroke. CLINICALTRIAL ClinicalTrials.gov NCT02462317; https://clinicaltrials.gov/study/NCT02462317; European clinical trials (EudraCT) 2010-022881-28; https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022881-28/FR INTERNATIONAL REGISTERED REPORT DERR1-10.2196/62951

  • La dysfonction sexuelle du patient neurologique

    by F. Michel, I. Bentellis, P.-L. Dequirez, X. Biardeau, F. Marcelli, M. De Seze, A. Even, E. Castel, L. Freton, C. Guillot-Tantay, et al.

  • Prospective study of the epidemiology of urinary tract infections at short term and mid-term after initiation of intermittent self-catheterisation

    by Isabelle Bolzonella, Pauline Roulette, Thibaut Brierre, Evelyne Castel-Lacanal, Michel Soulié, Xavier Gamé


  • Open Access

    How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity

    by Camille Mailho, Benoit Peyronnet, Marianne De Seze, Alexia Even, Maire‐Aimée Perrouin‐Verbe, Gérard Amarenco, Emmanuel Chartier‐Kastler, Loic Le Normand, Andrea Manunta, Gilles Karsenty, et al.

    Introduction: Neurogenic detrusor overactivity (NDO) has a major impact on patients' quality of life and can lead to upper urinary tract complications. Intradetrusor botulinum toxin type A injections are administered as second‐line treatment to these patients following the failure of anticholinergic agents. The aim of the DETOX 2 study is to propose a consensus definition of the failure of intradetrusor botulinum toxin injections for NDO in patients presenting spinal cord injury, spina bifida, or multiple sclerosis (MS) with self‐catheterization.Method: This study followed the method adopted by the French National Authority for Health for recommendations by consensus. Based on a review of the literature and a preliminary survey, a steering committee compiled a questionnaire and selected a rating group comprising 16 experts from the Neuro‐Urology Committee of the French Urology Association (cnuAFU) and Genulf. The experts were asked to complete the online questionnaire. At the end of the first round, all participants came together to discuss any disagreements and a second‐round online questionnaire was completed to reach a consensus.Results: Thirteen of the 16 experts approached completed both rounds of questionnaires. A strong consensus was reached for two proposals (median score = 9/10) which were therefore included in the definition from the first round: at least one repeat injection of the same botulinum toxin at the same dose must be given to rule out failure on technical grounds and a duration of efficacy 40 cm H2O and/or a compliance issue and/or persistence of urinary incontinence and/or urgency and/or a number of daily self‐catheterizations >8/day and/or efficacy <3 months. This study will help to standardize research on the failure of the intradetrusor botulinum toxin for NDO in clinical practice and clinical research.


  • Neuromodulation sacrée pour trouble de la vidange vésicale : expérience d’un centre universitaire français

    by Q. Ducrot, T. Brierre, P. Roulette, M. Soulié, E. Castel-Lacanal, X. Gamé